DK1802658T3 - Kimære og humaniserede monoklonale antistoffer mod interleukin-13 - Google Patents

Kimære og humaniserede monoklonale antistoffer mod interleukin-13

Info

Publication number: DK1802658T3
Authority: DK; Denmark
Prior art keywords: interleukin; chimeric; monoclonal antibodies; humanized monoclonal; humanized
Prior art date: 2004-07-01

Application number

DK05757024.4T

Other languages

English (en)

Inventor

Claire Ashman

Martin John Cassidy

Jonathan Henry Ellis

Trevor Anthony Kenneth Wattam

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-07-01

Filing date

2005-06-30

Publication date

2012-03-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35521159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1802658(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-07-01 Priority claimed from GBGB0414799.7A external-priority patent/GB0414799D0/en

2004-10-25 Priority claimed from GB0423675A external-priority patent/GB0423675D0/en

2005-06-30 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2012-03-12 Application granted granted Critical

2012-03-12 Publication of DK1802658T3 publication Critical patent/DK1802658T3/da

Links

102000003816 Interleukin-13 Human genes 0.000 title 1
108090000176 Interleukin-13 Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Pulmonology (AREA)
Biophysics (AREA)
Tropical Medicine & Parasitology (AREA)
Neurology (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Oncology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

DK05757024.4T 2004-07-01 2005-06-30 Kimære og humaniserede monoklonale antistoffer mod interleukin-13 DK1802658T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB0414799.7A GB0414799D0 (en)	2004-07-01	2004-07-01	Immunoglobulins
GB0423675A GB0423675D0 (en)	2004-10-25	2004-10-25	Immunoglobulins
PCT/GB2005/002581 WO2006003407A2 (en)	2004-07-01	2005-06-30	Chimeric and humanised monoclonal antibodies against inteleukin- 13

Publications (1)

Publication Number	Publication Date
DK1802658T3 true DK1802658T3 (da)	2012-03-12

Family

ID=35521159

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK05757024.4T DK1802658T3 (da)	2004-07-01	2005-06-30	Kimære og humaniserede monoklonale antistoffer mod interleukin-13

Country Status (26)

Country	Link
US (2)	US7807788B2 (da)
EP (2)	EP2436697B1 (da)
JP (1)	JP5102616B2 (da)
KR (1)	KR20070034609A (da)
AR (1)	AR049565A1 (da)
AT (1)	ATE535545T1 (da)
AU (1)	AU2005259025B2 (da)
BR (1)	BRPI0512826A (da)
CA (1)	CA2571799A1 (da)
CY (1)	CY1112372T1 (da)
DK (1)	DK1802658T3 (da)
ES (2)	ES2456897T3 (da)
HR (1)	HRP20120139T1 (da)
IL (1)	IL180152A0 (da)
MA (1)	MA28726B1 (da)
MX (1)	MX2007000026A (da)
NO (1)	NO20070189L (da)
NZ (1)	NZ552063A (da)
PE (1)	PE20060376A1 (da)
PL (1)	PL1802658T3 (da)
PT (1)	PT1802658E (da)
RU (1)	RU2404192C2 (da)
SG (1)	SG153878A1 (da)
SI (1)	SI1802658T1 (da)
TW (1)	TWI307630B (da)
WO (1)	WO2006003407A2 (da)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0407315D0 (en)	2003-07-15	2004-05-05	Cambridge Antibody Tech	Human antibody molecules
KR101073590B1 (ko) *	2003-07-15	2011-10-14	메디뮨 리미티드	Ｉｌ-13에 대한 인간 항체 분자
KR20150064250A (ko)	2003-12-23	2015-06-10	제넨테크, 인크.	신규 항-ｉｌ１３ 항체 및 그 용도
AR049390A1 (es)	2004-06-09	2006-07-26	Wyeth Corp	Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en)	2004-06-17	2009-03-10	Wyeth	IL-13 binding agents
CA2587903A1 (en)	2004-11-17	2006-05-26	Amgen Fremont Inc.	Fully human monoclonal antibodies to il-13
US9072716B2 (en)	2005-04-15	2015-07-07	The United States of America, as represented by the Secretary Department of Health by Human Servies	Methods of treating and preventing inflammatory bowel disease involving IL-13 and NKT cells
SI1942939T2 (sl)	2005-09-30	2021-11-30	Medimmune Limited	Sestavek protitelesa proti interlevkinu-13
AU2006303452B2 (en)	2005-10-21	2011-06-09	Novartis Ag	Human antibodies against IL13 and therapeutic uses
GB0600488D0 (en) *	2006-01-11	2006-02-22	Glaxo Group Ltd	Immunoglobulins
JP2009523460A (ja) *	2006-01-24	2009-06-25	ドマンティスリミテッド	Ｉｌ−４および／またはｉｌ−１３に結合するリガンド
NZ599144A (en)	2006-09-08	2013-10-25	Abbott Lab	Interleukin -13 binding proteins
US7608693B2 (en)	2006-10-02	2009-10-27	Regeneron Pharmaceuticals, Inc.	High affinity human antibodies to human IL-4 receptor
MEP11109A (en) *	2006-10-02	2011-12-20		High affinity human antibodies to human il-4 receptor
DE102008053503B4 (de) *	2008-10-28	2011-04-28	Justus-Liebig-Universität Giessen	Immunologischer Test zum Nachweis von Autoantikörpern gegen testikuläre Antigene
GB0904214D0 (en)	2009-03-11	2009-04-22	Ucb Pharma Sa	Biological products
EA201190275A1 (ru) *	2009-05-28	2012-11-30	Глаксо Груп Лимитед	Белок, связывающий интерлейкин-13 (il-13)
KR101830596B1 (ko) *	2009-10-20	2018-02-22	애브비 인코포레이티드	단백질 ａ 친화성 크로마토그래피를 사용한 항―ｉｌ―１３ 항체의 분리 및 정제
WO2011119925A2 (en) *	2010-03-25	2011-09-29	Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Synthetic herpes simplex viruses for treatment of cancers
EP2652498B1 (en)	2010-12-16	2018-04-18	F.Hoffmann-La Roche Ag	Diagnosis and treatments relating to th2 inhibition
ES2900342T3 (es)	2012-08-21	2022-03-16	Sanofi Biotechnology	Métodos para tratar o prevenir el asma administrando un antagonista de IL-4R
TWI679019B (zh) *	2013-04-29	2019-12-11	法商賽諾菲公司	抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
TWI755763B (zh)	2013-06-04	2022-02-21	美商再生元醫藥公司	藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI634900B (zh)	2013-07-11	2018-09-11	再生元醫藥公司	藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
KR102332302B1 (ko)	2013-09-13	2021-12-01	제넨테크, 인크.	세포주에서 숙주 세포 단백질 및 재조합 폴리펩티드 생성물을 검출 및 정량화하기 위한 조성물 및 방법
CN105722532A (zh)	2013-09-13	2016-06-29	豪夫迈·罗氏有限公司	包含纯化的重组多肽的方法和组合物
MX2016005159A (es)	2013-10-23	2016-07-05	Genentech Inc	Metodos de diagnostico y tratamiento de trastornos eosinofilicos.
CN106164675B (zh)	2014-02-07	2019-04-23	免疫医疗有限责任公司	检测人类骨膜蛋白的新型测定
BR112016018980A2 (pt)	2014-02-21	2017-10-10	Genentech Inc	método de tratamento de um distúrbio, anticorpo multiespecífico, ácido nucleico isolado, célula hospedeira, métodos de produzir um anticorpo, de produção de uma metade de anticorpo ou de um anticorpo multiespecífico e de produção de um anticorpo multiespecífico, imunoconjugado e formulação farmacêutica
WO2015155710A1 (en)	2014-04-11	2015-10-15	Novartis Ag	Methods of selectively treating asthma using il-13 antagonists
PT3110848T (pt)	2014-09-24	2024-03-05	Regeneron Pharma	Métodos para tratamento de infeção cutânea por administração de um antagonista do il-4r
AU2015346150B2 (en)	2014-11-14	2021-08-19	Regeneron Pharmaceuticals, Inc.	Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
CA2977285A1 (en)	2015-03-16	2016-09-22	F. Hoffmann-La Roche Ag	Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
ITUB20155097A1 (it) *	2015-11-05	2017-05-05	Biouniversa Srl	Anticorpi umanizzati anti-BAG3
AU2017258097B2 (en)	2016-04-27	2019-10-24	Abbvie Inc.	Methods of treatment of diseases in which IL-13 activity is detrimental using anti-IL-13 antibodies
EP3459972A4 (en) *	2016-05-18	2020-06-24	Shanghai Pharmaexplorer Co., Ltd.	IL-13 ANTIBODIES AND PRODUCTION METHOD AND USE THEREOF
MX2019002344A (es)	2016-09-01	2019-09-06	Regeneron Pharma	Metodos de prevenir o tratar la alergia administrando un antagonista de il-4r.
WO2018057776A1 (en)	2016-09-22	2018-03-29	Regeneron Pharmaceuticals, Inc.	Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
TWI784988B (zh)	2016-12-01	2022-12-01	美商再生元醫藥公司	治療發炎症狀的方法
CN110087530A (zh)	2016-12-07	2019-08-02	普罗根尼蒂公司	胃肠道检测方法、装置和系统
WO2018183932A1 (en)	2017-03-30	2018-10-04	Progenity Inc.	Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
WO2019028367A1 (en)	2017-08-04	2019-02-07	Regeneron Pharmaceuticals, Inc.	METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
KR102785099B1 (ko)	2017-10-30	2025-03-26	사노피 바이오테크놀로지	Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
CN111787947A (zh)	2018-02-09	2020-10-16	豪夫迈·罗氏有限公司	用于肥大细胞介导的炎性疾病的治疗和诊断方法
KR20210010518A (ko)	2018-05-13	2021-01-27	리제너론 파아마슈티컬스, 인크.	Il-4r 억제제를 투여하여 아토피성 피부염을 치료하는 방법
WO2020092015A1 (en)	2018-11-02	2020-05-07	University Of Rochester	Therapeutic mitigation of epithelial infection
CN113348011B (zh)	2018-11-19	2023-04-18	比奥拉治疗股份有限公司	用生物治疗剂治疗疾病的方法和装置
US20220062352A1 (en) *	2018-12-03	2022-03-03	Demata Therapeutics, LLC	Compositions for the treatment of conditions
MA55204A (fr)	2019-03-06	2022-01-12	Regeneron Pharma	Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer
CN113597328A (zh)	2019-03-21	2021-11-02	瑞泽恩制药公司	用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
KR20220042217A (ko)	2019-08-05	2022-04-04	리제너론 파아마슈티컬스, 인크.	Il-4r 길항제를 투여함에 의해 알레르기를 치료하고 알레르겐-특이적 면역치료요법을 증진시키기 위한 방법
SG11202113310UA (en)	2019-08-05	2021-12-30	Regeneron Pharma	Methods for treating atopic dermatitis by administering an il-4r antagonist
US11707610B2 (en)	2019-12-13	2023-07-25	Biora Therapeutics, Inc.	Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2023130010A1 (en)	2021-12-30	2023-07-06	Regeneron Pharmaceuticals, Inc.	Methods for attenuating atopic march by administering an il-4/il-13 antagonist
EP4227321A1 (en) *	2022-02-10	2023-08-16	AVA Lifescience GmbH	Antibodies targeting the b-cell receptor of chronic lymphocytic leukemia (cll) for use in treatment of cll
WO2025049345A1 (en)	2023-08-25	2025-03-06	Proteologix Us Inc.	Anti-il-13 multispecific antibody constructs and uses thereof

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DD266710A3 (de)	1983-06-06	1989-04-12	Ve Forschungszentrum Biotechnologie	Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en)	1984-10-30	1989-11-07	Phillips Petroleum Company	Transformation of yeasts of the genus pichia
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
GB8610600D0 (en)	1986-04-30	1986-06-04	Novo Industri As	Transformation of trichoderma
DE3883899T3 (de)	1987-03-18	1999-04-22	Sb2, Inc., Danville, Calif.	Geänderte antikörper.
US6051231A (en) *	1988-09-01	2000-04-18	Bayer Corporation	Antiviral methods and prepations
KR0184860B1 (ko)	1988-11-11	1999-04-01	메디칼 리써어치 카운실	단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
FR2646437B1 (fr)	1989-04-28	1991-08-30	Transgene Sa	Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US6291158B1 (en)	1989-05-16	2001-09-18	Scripps Research Institute	Method for tapping the immunological repertoire
EP0402226A1 (en)	1989-06-06	1990-12-12	Institut National De La Recherche Agronomique	Transformation vectors for yeast yarrowia
US6172197B1 (en)	1991-07-10	2001-01-09	Medical Research Council	Methods for producing members of specific binding pairs
WO1993002108A1 (en)	1991-07-25	1993-02-04	Idec Pharmaceuticals Corporation	Recombinant antibodies for human therapy
DK0605522T3 (da)	1991-09-23	2000-01-17	Medical Res Council	Fremgangsmåde til fremstilling af humaniserede antistoffer
GB9122820D0 (en)	1991-10-28	1991-12-11	Wellcome Found	Stabilised antibodies
WO1993008829A1 (en)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions that mediate killing of hiv-infected cells
GB9127376D0 (en)	1991-12-24	1992-02-19	Wellcome Found	Amidino derivatives
GB9203459D0 (en)	1992-02-19	1992-04-08	Scotgen Ltd	Antibodies with germ-line variable regions
NZ251092A (en)	1992-04-02	1996-12-20	Smithkline Beecham Corp	4-cyano-cyclohexane derivatives; medicaments; used in treating asthma
ATE149570T1 (de)	1992-08-17	1997-03-15	Genentech Inc	Bispezifische immunoadhesine
GB2294267B (en)	1993-06-03	1996-11-20	Therapeutic Antibodies Inc	Anti-TNFalpha Fab fragments derived from polyclonal IgG antibodies
US5429746A (en)	1994-02-22	1995-07-04	Smith Kline Beecham Corporation	Antibody purification
SI0957087T1 (en)	1994-06-15	2003-04-30	The Wellcome Foundation Limited	Intermediates useful in the preparation of enzyme inhibitors
US5739277A (en)	1995-04-14	1998-04-14	Genentech Inc.	Altered polypeptides with increased half-life
MY117948A (en)	1997-01-13	2004-08-30	Glaxo Group Ltd	Nitride oxide synthase inhibitors.
DE19723722A1 (de)	1997-05-30	1998-12-10	Schering Ag	Nichtsteroidale Gestagene
WO1999016766A1 (fr)	1997-10-01	1999-04-08	Kyowa Hakko Kogyo Co., Ltd.	Derives de benzodioxole
US6506766B1 (en)	1998-02-13	2003-01-14	Abbott Laboratories	Glucocortiocoid-selective antinflammatory agents
AU3328499A (en)	1998-03-14	1999-10-11	Byk Gulden Lomberg Chemische Fabrik Gmbh	Phthalazinone pde iii/iv inhibitors
GB9806530D0 (en)	1998-03-26	1998-05-27	Glaxo Group Ltd	Inflammatory mediator
WO1999055369A1 (en)	1998-04-28	1999-11-04	Smithkline Beecham Corporation	Monoclonal antibodies with reduced immunogenicity
GB9811599D0 (en)	1998-05-30	1998-07-29	Glaxo Group Ltd	Nitric oxide synthase inhibitors
AU2750800A (en) *	1999-02-01	2000-08-18	Amgen Canada Inc.	Materials and methods to inhibit hodgkin and reed sternberg cell growth
AU4501800A (en)	1999-05-04	2000-11-17	American Home Products Corporation	Tetracyclic progesterone receptor modulator compounds and methods
ES2165768B1 (es)	1999-07-14	2003-04-01	Almirall Prodesfarma Sa	Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US6263209B1 (en)	1999-07-28	2001-07-17	Motorola, Inc.	Method and apparatus in a wireless communication system for creating a learning function
CO5180649A1 (es)	1999-09-01	2002-07-30	Abbott Lab	Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes
WO2002026722A1 (en)	2000-09-29	2002-04-04	Glaxo Group Limited	Morpholin-acetamide derivatives for the treatment of inflammatory diseases
GB0031179D0 (en)	2000-12-21	2001-01-31	Glaxo Group Ltd	Nitric oxide synthase inhibitors
US6484903B2 (en)	2001-01-09	2002-11-26	Riverwood International Corporation	Carton with an improved dispensing feature in combination with a unique handle
GB0103630D0 (en)	2001-02-14	2001-03-28	Glaxo Group Ltd	Chemical compounds
GB0105360D0 (en)	2001-03-03	2001-04-18	Glaxo Group Ltd	Chimaeric immunogens
DE60220887T2 (de)	2001-03-08	2008-02-28	Glaxo Group Ltd., Greenford	Agonisten von beta-adrenorezeptoren
US7045658B2 (en)	2001-03-22	2006-05-16	Glaxo Group Limited	Formailide derivatives as beta2-adrenoreceptor agonists
CN1585633B (zh)	2001-09-14	2010-10-27	葛兰素集团有限公司	治疗呼吸疾病的苯乙醇胺衍生物
AU2002337496A1 (en) *	2001-09-20	2003-04-28	Pioneer Corporation	Drive circuit for light emitting elements
EP1467982B8 (en)	2002-01-14	2007-04-11	Boehringer Ingelheim Pharmaceuticals Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them, and uses thereof
CA2473886C (en)	2002-01-22	2012-08-21	The Regents Of The University Of California	Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
GB0204719D0 (en)	2002-02-28	2002-04-17	Glaxo Group Ltd	Medicinal compounds
CA2480059C (en) *	2002-03-22	2015-11-24	Amrad Operations Pty. Ltd.	Monoclonal antibody against interleukin-13 receptor alpha 1 (il-13r.alpha.1)
CA2477764A1 (en)	2002-03-26	2003-10-09	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
RS51097B (sr)	2002-03-26	2010-10-31	Boehringer Ingelheim Pharmaceuticals Inc.	Glukokortikoidni mimetici,postupci za njihovo dobijanje, farmaceutski preparati i njihova primena
DE10215316C1 (de)	2002-04-02	2003-12-18	Schering Ag	Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
AU2003223497A1 (en) *	2002-04-05	2003-10-27	Centocor, Inc.	Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
WO2003086294A2 (en)	2002-04-11	2003-10-23	Merck & Co., Inc.	1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators
JP2005525404A (ja) *	2002-05-01	2005-08-25	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	Ｈｉｖ感染およびａｉｄｓを処置するためにサイトカインアンタゴニストを使用する方法
US7186864B2 (en)	2002-05-29	2007-03-06	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en)	2002-06-06	2006-07-11	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
SI1521733T1 (sl)	2002-07-08	2014-10-30	Pfizer Products Inc.	Modulatorji glukokortikoidnega receptorja
EP1575502B1 (en)	2002-07-18	2010-01-20	Bristol-Myers Squibb Company	Compositions and methods involving nuclear hormone receptor site ii
PL375442A1 (en)	2002-07-18	2005-11-28	Bristol-Myers Squibb Company	Modulators of the glucocorticoid receptor and method
GB0216648D0 (en)	2002-07-18	2002-08-28	Lonza Biologics Plc	Method of expressing recombinant protein in CHO cells
PT1944322E (pt) *	2002-07-19	2015-07-01	Abbvie Biotechnology Ltd	Tratamento de distúrbios relacionados com tnf-alfa
WO2004018429A2 (en)	2002-08-21	2004-03-04	Boehringer Ingelheim Pharmaceuticals, Inc.	Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
ATE442367T1 (de)	2002-09-16	2009-09-15	Glaxo Group Ltd	Pyrazolo(3,4-b)pyridinverbindungen und ihre verwendung als phosphodiesterasinhibitoren
EP1542996A4 (en)	2002-09-20	2009-11-18	Merck & Co Inc	OCTAHYDRO-2H-NAPHTOc1,2-F INDOL-4-CARBONSUUREAMIDE DERIVATIVES AS SELECTIVE MODULATORS OF THE GLUCOCORTICOID RECEPTOR
GB0407315D0 (en)	2003-07-15	2004-05-05	Cambridge Antibody Tech	Human antibody molecules
US7790405B2 (en) *	2004-04-26	2010-09-07	Centocor, Inc.	Solution phase biopanning method using engineered decoy proteins
US7501121B2 (en) *	2004-06-17	2009-03-10	Wyeth	IL-13 binding agents
AR049390A1 (es) *	2004-06-09	2006-07-26	Wyeth Corp	Anticuerpos contra la interleuquina-13 humana y usos de los mismos

2005
- 2005-06-29 TW TW094121993A patent/TWI307630B/zh not_active IP Right Cessation
- 2005-06-30 RU RU2007103826/10A patent/RU2404192C2/ru not_active IP Right Cessation
- 2005-06-30 WO PCT/GB2005/002581 patent/WO2006003407A2/en active Application Filing
- 2005-06-30 PL PL05757024T patent/PL1802658T3/pl unknown
- 2005-06-30 PT PT05757024T patent/PT1802658E/pt unknown
- 2005-06-30 AT AT05757024T patent/ATE535545T1/de active
- 2005-06-30 ES ES11181891.0T patent/ES2456897T3/es not_active Expired - Lifetime
- 2005-06-30 EP EP11181891.0A patent/EP2436697B1/en not_active Revoked
- 2005-06-30 SG SG200904563-4A patent/SG153878A1/en unknown
- 2005-06-30 SI SI200531473T patent/SI1802658T1/sl unknown
- 2005-06-30 KR KR1020077002166A patent/KR20070034609A/ko not_active Abandoned
- 2005-06-30 HR HR20120139T patent/HRP20120139T1/hr unknown
- 2005-06-30 US US11/570,736 patent/US7807788B2/en not_active Expired - Fee Related
- 2005-06-30 BR BRPI0512826-9A patent/BRPI0512826A/pt not_active IP Right Cessation
- 2005-06-30 AU AU2005259025A patent/AU2005259025B2/en not_active Ceased
- 2005-06-30 MX MX2007000026A patent/MX2007000026A/es active IP Right Grant
- 2005-06-30 AR ARP050102731A patent/AR049565A1/es unknown
- 2005-06-30 ES ES05757024T patent/ES2378173T3/es not_active Expired - Lifetime
- 2005-06-30 JP JP2007518695A patent/JP5102616B2/ja not_active Expired - Fee Related
- 2005-06-30 DK DK05757024.4T patent/DK1802658T3/da active
- 2005-06-30 CA CA002571799A patent/CA2571799A1/en not_active Abandoned
- 2005-06-30 EP EP05757024A patent/EP1802658B1/en not_active Expired - Lifetime
- 2005-06-30 PE PE2005000762A patent/PE20060376A1/es not_active Application Discontinuation
- 2005-06-30 NZ NZ552063A patent/NZ552063A/en not_active IP Right Cessation
2006
- 2006-12-18 IL IL180152A patent/IL180152A0/en unknown
- 2006-12-29 MA MA29577A patent/MA28726B1/fr unknown
2007
- 2007-01-11 NO NO20070189A patent/NO20070189L/no not_active Application Discontinuation
2010
- 2010-08-24 US US12/862,235 patent/US20110243928A1/en not_active Abandoned
2012
- 2012-02-21 CY CY20121100172T patent/CY1112372T1/el unknown

Also Published As

Publication number	Publication date
MX2007000026A (es)	2007-03-07
PE20060376A1 (es)	2006-06-02
RU2007103826A (ru)	2008-08-10
EP2436697B1 (en)	2014-03-05
SG153878A1 (en)	2009-07-29
MA28726B1 (fr)	2007-07-02
TW200612985A (en)	2006-05-01
CY1112372T1 (el)	2015-12-09
US7807788B2 (en)	2010-10-05
US20070258979A1 (en)	2007-11-08
AR049565A1 (es)	2006-08-16
IL180152A0 (en)	2007-06-03
JP5102616B2 (ja)	2012-12-19
SI1802658T1 (sl)	2012-03-30
NZ552063A (en)	2010-01-29
KR20070034609A (ko)	2007-03-28
PT1802658E (pt)	2012-03-06
WO2006003407A2 (en)	2006-01-12
EP1802658B1 (en)	2011-11-30
ES2456897T3 (es)	2014-04-23
HRP20120139T1 (hr)	2012-03-31
RU2404192C2 (ru)	2010-11-20
TWI307630B (en)	2009-03-21
JP2008511542A (ja)	2008-04-17
AU2005259025B2 (en)	2012-01-19
EP1802658A2 (en)	2007-07-04
ES2378173T3 (es)	2012-04-09
ATE535545T1 (de)	2011-12-15
PL1802658T3 (pl)	2012-04-30
US20110243928A1 (en)	2011-10-06
CA2571799A1 (en)	2006-01-12
AU2005259025A1 (en)	2006-01-12
BRPI0512826A (pt)	2008-04-08
NO20070189L (no)	2007-03-29
WO2006003407A3 (en)	2006-04-27
EP2436697A1 (en)	2012-04-04

Publication	Publication Date	Title
DK1802658T3 (da)	2012-03-12	Kimære og humaniserede monoklonale antistoffer mod interleukin-13
DK1960434T3 (da)	2012-10-15	Monoklonale, humane antistoffer mod Fucosyl-GM1 og fremgangsmåder til anvendelse af anti-Fucosyl-GM1
EP1947178A4 (en)	2009-03-11	MONOCLONAL HUMAN ANTIBODY BINDING TO HUMAN GM-CSF AND ANTIGEN BINDING SITE OF THIS ANTIBODY
DK1794586T3 (da)	2013-05-13	Monoklonale antistoffer til progastrin
IL179672A (en)	2016-03-31	Monoclonal antibodies against 3 cd human
DK2177537T3 (da)	2011-12-12	Antistoffer til MAdCAM
DK1976877T3 (da)	2014-03-31	Monoklonale antistoffer mod amyloid-beta-protein og anvendelser heraf
IL191340A (en)	2015-08-31	Monoclonal antibodies against e8o
CY2012019I2 (el)	2015-08-05	Ανθρωπινα μονοκλωνα αντισωματα εναντια στο cd20
IL179102A0 (en)	2007-03-08	HUMANIZED Fc??RIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
DE60334076D1 (de)	2010-10-21	Monoklonaler anti-mensch-tenascin-Antikörper
IL206709A0 (en)	2011-07-31	Il-31 monoclonal antibodies
BRPI0908508A2 (pt)	2016-03-22	anticorpo monoclonal nkg2a anti-humano humanizado
IL191217A (en)	2015-10-29	Anti-17 mantle monoclonal antibody
PL1951760T5 (pl)	2023-09-18	Ludzkie przeciwciało monoklonalne wobec ludzkiego CD134 (OX40) i sposoby jego wytwarzania i stosowania
DK3332808T3 (da)	2020-12-14	Humaniserede L243-antistoffer
NO20052889D0 (no)	2005-06-14	Humane monoklonale antistoffer mot CD25
IL184152A0 (en)	2007-10-31	Monoclonal antibodies against nkg2a
NO20054351D0 (no)	2005-09-20	Monoklonalt antistoff og hybridom som produserer dette
ZA200805526B (en)	2009-10-28	Chimeric and humanised anti-human IL-13 antibodies
DK1664122T3 (da)	2010-06-28	Terapeutisk humaniserede antistoffer mod CD45-isoformer
DK1817343T3 (da)	2014-09-15	Humane monoklone antistoffer mod humant IL-4
BRPI0509495A2 (pt)	2016-10-11	anticorpo humanizado
PT1718678T (pt)	2017-12-29	Anticorpo monoclonal de tenascina anti-humano
FI20020807A0 (fi)	2002-04-29	Uusia humanisoituja anti-VAP-1 monoklonaalisia vasta-aineita